School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya 47500, Malaysia.
Health Sciences Division, Abu Dhabi Women's College, Higher Colleges of Technology, Abu Dhabi 41012, United Arab Emirates.
Int J Mol Sci. 2022 Aug 12;23(16):9001. doi: 10.3390/ijms23169001.
Ischemic heart disease (IHD) constitutes the leading global cause of mortality and morbidity. Although significant progress has been achieved in the diagnosis, treatment, and prognosis of IHD, more robust diagnostic biomarkers and therapeutic interventions are still needed to circumvent the increasing incidence of IHD. MicroRNAs (miRNAs) are critical regulators of cardiovascular function and are involved in various facets of cardiovascular biology. While the knowledge of the role of miRNAs in IHD as diagnostic biomarkers has improved, research emphasis on how miRNAs can be effectively used for diagnosis and prognosis of IHD is crucial. This review provides an overview of the biology, therapeutic and diagnostic potential, as well as the caveats of using miRNAs in IHD based on existing research.
缺血性心脏病（IHD）是全球主要的死亡和发病原因。尽管在 IHD 的诊断、治疗和预后方面已经取得了重大进展，但仍需要更强大的诊断生物标志物和治疗干预措施来规避 IHD 发病率的不断上升。microRNAs（miRNAs）是心血管功能的关键调节因子，参与心血管生物学的各个方面。虽然 miRNA 在 IHD 作为诊断生物标志物中的作用的知识已经有所提高，但研究重点是如何有效地将 miRNAs 用于 IHD 的诊断和预后。本综述根据现有研究，概述了 miRNA 在 IHD 中的生物学、治疗和诊断潜力以及使用 miRNA 的注意事项。
